A newly developed antimicrobial agent, balofloxacin (BLFX), was evaluated in vitro and in vivo. The results were as follows: 1) Antimicrobial activity: Minimal inhibitory concentrations (MICs) against 602 clinical isolates of 17 different species were determined and compared with those of five other drugs, ciprofloxacin (CPFX), tosufloxacin (TFLX), ofloxacin (OFLX), sparfloxacin (SPFX) and norfloxacin (NFLX). BLFX showed excellent antimicrobial activities against gram positive and negative bacteria. 2) Clinical efficacy anti adverse reactions: Eight patients with respiratory tract infection were treated with BLFX. Overall efficacy was excellent in 2 cases, good in 2, fair in 2, and not evaluated in 2. Side effects were not observed in any patients. As abnormal laboratory findings, elevation of GPT in one case and decreased hematocrit in another were observed. These changes were mild and improved rapidly after the completion of treatment, indicating that BLFX is a safe agent.
|Number of pages||6|
|Journal||Japanese Journal of Chemotherapy|
|Issue number||SUPPL. 5|
|Publication status||Published - 1995|
- balofloxacin (BLFX)
ASJC Scopus subject areas
- Pharmacology (medical)